Shares of Resmed Inc. (RMD) traded over 7% higher in pre-market on Thursday morning after the company’s third-quarter ...

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near-term risk from this therapy due to the higher cost and invasive surgery ...

Piper Sandler lowered the firm’s price target on ResMed (RMD) to $248 from $260 and keeps a Neutral rating on the shares. The firm notes the ...

Discover ResMed's Q3 2025 earnings highlights, including 8% revenue growth, margin expansion, new product launches, and strategic investments in ...

Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder.

Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder. The company manufactures continuous ...